Reading ALMS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALMS free→Reading ALMS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALMS free→QuarterlyIQ Insights · ALMS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Other Events. On March 28, 2026, Alumis Inc. (the “Company” or “Alumis”) issued a press release titled “Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis”. The Company is also filing slides presented by the Company at a late-breaking oral presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting on March 28,…
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Results of Operations and Financial Condition. On January 6, 2026, Alumis, Inc. (the “Company” or “Alumis”) announced that its preliminary unaudited cash, cash equivalents and marketable securities as of December 31, 2025 were approximately $308.6 million. The preliminary financial data included in this Current Report on Form 8-K (the “Report”) has been prepared by, and is the responsibility of Alumis management. PricewaterhouseCoopers LLP, the Company’s independent registered public accounti…
Other Events. On January 7, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 17,650,000 shares of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”). The price to the public in the offering…
Other Events. On January 6, 2026, Alumis Inc. (the “Company” or “Alumis”) issued a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program”. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference. Additionally, on January 6, 2026, the Company posted an updated corporate presentation to the investor section of its website. A copy of the corporate presentation is…
Other Events. On January 2, 2026, Alumis Inc. (the “Company”) and its wholly-owned subsidiary Acelyrin, Inc. (“Acelyrin”) issued a Notice of Material Breach and Notification of Claim for Indemnification to Climb Bio, Inc. (“Climb Bio”), after Climb Bio knowingly and willfully refused to pay a $3,000,000 Development Milestone payment due January 1, 2026 under the Asset Purchase Agreement, dated as of January 11, 2024, between Acelyrin, WH2, LLC and Tenet Medicines, Inc. (a wholly owned subsidi…
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. Merger Agreement As previously disclosed, on February 6, 2025, Alumis Inc., a Delaware corporation (“ Alumis ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with ACELYRIN, Inc., a Delaware corporation (“ ACELYRIN ”), and Arrow Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Alumis (“ Merger Sub ”). Pursuant to the Merger Agreement, Merger Sub will be merged with and into ACELYRIN and ACELY…
Other Events. A joint press release issued by Alumis and ACELYRIN on April 21, 2025 announcing the entrance into the Amended Agreement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 8.01, including Exhibit 99.1, is being furnished to the SEC and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or incorporated by reference in any filing under the Securities A…
Other Events. Collaboration and License Agreement On March 25, 2025, Alumis Inc. (the “Company”) entered into a collaboration and license agreement (the “Collaboration Agreement”) with Kaken Pharmaceutical Co., Ltd. (“Kaken”). Under the terms of the Collaboration Agreement, the Company granted to Kaken an exclusive right to develop, manufacture and commercialize ESK-001 for dermatology indications in Japan, with options to expand the license, subject to option payments and certain cost-sharin…
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2025, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Alumis Inc. (the “Company”) approved the Alumis Inc. Severance and Change in Control Plan (the “Severance Plan”). The purpose of the Severance Plan is to provide for the payment of severance and/or Change in Control (as defined in the Severa…
Results of Operations and Financial Condition. On February 6, 2025, Alumis disclosed in a press release regarding the Merger Agreement, among other things, that the preliminary, unaudited amount of Alumis’ cash, cash equivalents and marketable securities position as of December 31, 2024 is approximately $289 million. This amount is preliminary, unaudited and may change, was prepared by management and is based on the most current information available to management. Further, this amount is sub…
Entry into a Material Definitive Agreement. Merger Agreement On February 6, 2025, Alumis Inc., a Delaware corporation (“ Alumis ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with ACELYRIN, Inc., a Delaware corporation (“ ACELYRIN ”), and Arrow Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Alumis (“ Merger Sub ”). Pursuant to the Merger Agreement, Merger Sub will be merged with and into ACELYRIN and ACELYRIN will continue as the…
Other Events. In connection with the execution of the Merger Agreement, Alumis entered into Voting and Support Agreements (the “ Alumis Voting Agreements ”) with certain of ACELYRIN’s stockholders, including certain entities affiliated with Westlake Village BioPartners, certain entities affiliated with AyurMaya Capital Management, certain entities affiliated with Access Industries, Beth Seidenberg, Dan Becker and Mina Kim (collectively, the “ ACELYRIN Stockholders ”). Pursuant to the Alumis V…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.